No Data
No Data
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
Express News | Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy Designation For NXC-201
Several Insiders Invested In Immix Biopharma Flagging Positive News
Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation
Express News | Immix Biopharma Inc: On Track for Next Program Update in Q1 2025
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
Unlock the Full List